200 related articles for article (PubMed ID: 21730354)
1. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
Homminga I; Zwaan CM; Manz CY; Parker C; Bantia S; Smits WK; Higginbotham F; Pieters R; Meijerink JP
Blood; 2011 Aug; 118(8):2184-90. PubMed ID: 21730354
[TBL] [Abstract][Full Text] [Related]
2. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
[TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan K; Ravandi F; Bantia S; Franklin A; Gandhi V
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):458-66. PubMed ID: 23773454
[TBL] [Abstract][Full Text] [Related]
4. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
[TBL] [Abstract][Full Text] [Related]
5. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
6. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
7. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
8. High ENT1 and DCK gene expression levels are a potential biomarker to predict favorable response to nelarabine therapy in T-cell acute lymphoblastic leukemia.
Akahane K; Murakami Y; Kagami K; Abe M; Harama D; Shinohara T; Watanabe A; Goi K; Nishi R; Yamauchi T; Kimura S; Takita J; Look AT; Minegishi M; Sugita K; Inukai T
Hematol Oncol; 2019 Oct; 37(4):516-519. PubMed ID: 31335977
[No Abstract] [Full Text] [Related]
9. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase.
Rodriguez CO; Mitchell BS; Ayres M; Eriksson S; Gandhi V
Cancer Res; 2002 Jun; 62(11):3100-5. PubMed ID: 12036920
[TBL] [Abstract][Full Text] [Related]
10. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia.
Stam RW; den Boer ML; Meijerink JP; Ebus ME; Peters GJ; Noordhuis P; Janka-Schaub GE; Armstrong SA; Korsmeyer SJ; Pieters R
Blood; 2003 Feb; 101(4):1270-6. PubMed ID: 12406912
[TBL] [Abstract][Full Text] [Related]
11. Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.
Larson RA
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S13-20. PubMed ID: 18086342
[TBL] [Abstract][Full Text] [Related]
12. Nelarabine: a novel purine antimetabolite antineoplastic agent.
Buie LW; Epstein SS; Lindley CM
Clin Ther; 2007 Sep; 29(9):1887-99. PubMed ID: 18035189
[TBL] [Abstract][Full Text] [Related]
13. Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
BMC Cancer; 2014 Jul; 14():547. PubMed ID: 25070259
[TBL] [Abstract][Full Text] [Related]
14. Determinants of sensitivity of human T-cell leukemia CCRF-CEM cells to immucillin-H.
Huang M; Wang Y; Gu J; Yang J; Noel K; Mitchell BS; Schramm VL; Graves LM
Leuk Res; 2008 Aug; 32(8):1268-78. PubMed ID: 18279955
[TBL] [Abstract][Full Text] [Related]
15. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI
Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921
[TBL] [Abstract][Full Text] [Related]
16. Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?
Gore L; Stelljes M; Quinones R
Semin Oncol; 2007 Dec; 34(6 Suppl 5):S35-9. PubMed ID: 18086346
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
[TBL] [Abstract][Full Text] [Related]
18. Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Apr; 34(4):1657-62. PubMed ID: 24692694
[TBL] [Abstract][Full Text] [Related]
19. Older and new purine nucleoside analogs for patients with acute leukemias.
Robak P; Robak T
Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
[TBL] [Abstract][Full Text] [Related]
20. Forodesine (BCX-1777, Immucillin H)--a new purine nucleoside analogue: mechanism of action and potential clinical application.
Korycka A; Błoński JZ; Robak T
Mini Rev Med Chem; 2007 Sep; 7(9):976-83. PubMed ID: 17897085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
